Instrument Inactif

Communiqués KARA THER

Actions

KRTX

US48576A1007

Communiqués

KARA THER : Acquisition/Asset Disposal - Form 8-K	18/03	PU
Karuna Therapeutics : Material Event - Form 8-K	01/03	PU
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update	22/02	BU
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	14/02	BU
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	31/12	BU
Bristol-Myers, Rocket Lab gain; Nike, Cummins Engine fall on Friday, 12/22/2023	22/12	AQ
Stock market today: Wall Street ticks closer to record highs to cap its 8th straight winning week	22/12	AQ
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio	22/12	AQ
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders	22/12	BU
BMS strikes $14bn deal for Karuna Therapeutics	22/12	AQ
Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers	22/12	PR
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia	15/12	BU
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia	29/11	BU
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	20/11	AQ
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	16/11	BU
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates	02/11	BU
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress	01/11	BU
Karuna Therapeutics to Present at Upcoming Investor Conferences	01/11	BU
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023	19/10/23	BU
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology Congress	05/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués KARA THER

Actions

KRTX

US48576A1007

Communiqués

Filtres